pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Merck KGaA readies tariff refunds worth €40M for life science customers

Merck KGaA said it expects to receive tariff refunds for its life science business through the end of 2026 after the US Supreme Court blocked some of President Donald Trump’s levies. The German conglomerate will ...

Aug 6, 2026·read at Endpoints ↗

August 6, 2026 07:30 AM EDT PharmaManufacturing Mer­ck KGaA read­ies tar­iff re­funds worth €40M for life sci­ence cus­tomers Ayisha Sharma News Reporter Mer­ck KGaA said it ex­pects to re­ceive tar­iff re­funds for its life sci­ence busi­ness through the end of 2026 af­ter the US Supreme Court blocked … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
82 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Merck KGaA2

related stories

  • 1h agoEmergent cuts 93 roles, 21 vacant positionsBioSpace
  • 1d agoSanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’Fierce Biotech
  • Jul 30Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continuesFierce Biotech
  • Jun 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesBioPharma Dive
  • May 13Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boostEndpoints